India is emerging as an epicenter of the dengue disease burden with an estimated 20-40 million clinically apparent infections per year. As currently there is no vaccine available in India and hence, there is a need for an affordable vaccine for the prevention of Dengue infection. The National Biopharma Mission is committed to support development of vaccine candidates for effective management of dengue.
|
Vaccine candidate |
Name of grantee |
Development Phase Supported |
Environmental and Health Risk Management Plan (EHRMP) |
|
Live attenuated |
Indian Immunologicals Limited |
Pre-clinical and Phase I CT material generation |
Click Here |
| Recombinant |
Sun Pharmaceutical Industries Limited (SPIL) and Sun Pharma Advanced Research Company Ltd (SPARC) |
Toxicity Studies |
|